We are international
• treatment options TEXT SIZE   
clinical trials    back

Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets CS1, a cell surface glycoprotein highly expressed on myeloma cells but minimally expressed on normal cells. Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.


08.30.12   Clinical Trial Fact Sheet for the ELOQUENT - 1 Trial

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma.

The Eloquent Trial fact sheets are also available in German, French, Italian, Spanish, and Dutch.

08.30.12   Clinical Trial Fact Sheet for the ELOQUENT - 2 Trial
Phase III Randomized, Open-label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

08.29.12   Open Clinical Trials at clinicaltrials.gov